In this regard, [89Zr]-anti-PD-1 (immuno-PET) may probably perform similarly well in other lung cancer subtypes for which immunotherapy has been approved in frontline treatment or as subsequent lines (KRAS or BRAF mutant lung tumors). Here, BRAF is linked to lung carcinoma.